SCHEMBL3784738

SCHEMBL3784738

Nc1cccc(Cl)c1C1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
ALDH1A1 P00352 3/20 0.45
NR4A2 P43354 1/20 0.45
ACHE P22303 2/20 0.42
OPRL1 P41146 5/20 0.40
HTR5A P47898 4/20 0.40
HTR2C P28335 4/20 0.40
HTR1A P08908 3/20 0.40
HTR7 P34969 3/20 0.40
HTR1D P28221 2/20 0.40
HTR2A P28223 2/20 0.40
HTR3A P46098 1/20 0.40
HTR6 P50406 1/20 0.40
HRH1 P35367 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30069349 1.00 TSHR (0.46) TSHRALDH1A1NR4A2ACHEOPRL1
SCHEMBL3789871 0.92 TSHR (0.43) TSHRALDH1A1NR4A2ACHEOPRL1
SCHEMBL3793155 0.92 TSHR (0.43) TSHRALDH1A1NR4A2ACHEOPRL1
SCHEMBL3791245 0.90 TSHR (0.41) TSHRALDH1A1NR4A2ACHEOPRL1
Nitrogen SCHEMBL11050859 0.87 ALDH1A1 (0.40) TSHRALDH1A1NR4A2ACHEOPRL1
SCHEMBL10387633 0.84 OPRL1 (0.49) TSHRALDH1A1ACHEOPRL1SMN1; SMN2
SCHEMBL3785910 0.76 SMN1; SMN2 (0.41) ALDH1A1ACHEOPRL1HTR2CHTR2A
SCHEMBL12290554 0.75 SMN1; SMN2 (0.48) TSHRALDH1A1ACHEOPRL1HTR5A
SCHEMBL25165595 0.74 OPRL1 (0.40) ALDH1A1ACHEOPRL1HTR5AHTR2C
SCHEMBL2044126 0.74 OPRL1 (0.40) ALDH1A1ACHEOPRL1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115611924-A PD-1/PD-L1 inhibitor and preparation method and application thereof 上海华汇拓医药科技有限公司 2023-01-17 CN disclosed
WO-2022237649-A1 EXOCYCLIC AMINO QUINAZOLINE DERIVATIVES AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2022-11-17 WO disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 TSHR 1688/4885ALDH1A1 4339/4885NR4A2 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.